The DOI matches its Crossref record.
Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents
Abstract
We assessed the prevalence of hypoglycemic symptoms in patients (aged 40–65 yr) treated with oral hypoglycemic agents (OHAs) attending routine diabetes clinics at our hospital. Symptoms were experienced during the previous 6 mo in 41 of 203 (20.2%) patients treated with sulfonylureas but in none of the 16 patients treated with metformin alone. Hypoglycemic symptoms were experienced at least monthly in 5.9% and less frequently in 14.3% of patients. The prevalence of symptoms decreased with increasing duration of sulfonylurea administration (P < .01). Mean glycosylated hemoglobin and postprandial plasma glucose were significantly lower in patients reporting hypoglycemic symptoms than in those without symptoms (P < .001). The prevalence of hypoglycemic symptoms was significantly higher in patients treated with glyburide than in patients treated with gliclazide (P < .01) or chlorpropamide (P < .05). The prevalence of symptoms was higher in patients taking medications in addition to OHAs (P < .01). Ten (24%) of the patients who experienced hypoglycemic symptoms were taking drugs that may potentiate sulfonylureas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 480
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2008) · Diabetes Care · doi:10.2337/dc08-1171 · Cited by 426
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Bradley, C., & Lewis, K. S. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01421.x · Cited by 379
Hypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Sulphonylurea action revisited: the post-cloning era
Gribble, F. M., & Reimann, F. (2003) · Diabetologia · doi:10.1007/s00125-003-1143-3 · Cited by 284
“Chlorpropamide, for example, has been found to produce fewer hypoglycaemic side effects than glibenclamide, even though both drugs have prolonged plasma half lives [95, 96, 97].”
Schernthaner, G., Grimaldi, A., Di Mario, U., Drzewoski, J., Kempler, P., Kvapil, M., Novials, A., Rottiers, R., Rutten, G. E. H. M., & Shaw, K. M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01381.x · Cited by 271
Symptoms of hypoglycaemia in people with diabetes
McAulay, V., Deary, I. J., & Frier, B. M. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00620.x · Cited by 264
Individual Sulfonylureas and Serious Hypoglycemia in Older People
Shorr, R. I., Ray, W. A., Daugherty, J. R., & Griffin, M. R. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb03729.x · Cited by 221
Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes
Davis, R. E., Morrissey, M., Peters, J. R., Wittrup-Jensen, K., Kennedy-Martin, T., & Currie, C. J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x61929 · Cited by 218
Rates of hypoglycemia in users of sulfonylureas
Van Staa, T., Abenhaim, L., & Monette, J. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00024-3 · Cited by 211
Drug-Induced Hypoglycemic Coma in 102 Diabetic Patients
Ben-Ami, H., Nagachandran, P., Mendelson, A., & Edoute, Y. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.3.281 · Cited by 201
Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men
Matyka, K., Evans, M., Lomas, J., Cranston, I., Macdonald, I., & Amiel, S. A. (1997) · Diabetes Care · doi:10.2337/diacare.20.2.135 · Cited by 195
“While most work on this topic has been done in young people with and without type I diabetes, profound neuroglycopenia is a significant problem for patients with type II diabetes treated with sulfonylureas (15-19).”
BackgroundWright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.010 · Cited by 153
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Stahl, M., & Berger, W. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00110.x · Cited by 125
Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.
Boyle, P. J., Justice, K., Krentz, A. J., Nagy, R. J., & Schade, D. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.3.8445035 · Cited by 125
Exercise-related hypoglycemia in diabetes mellitus
Younk, L. M., Mikeladze, M., Tate, D., & Davis, S. N. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.78 · Cited by 114
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Gliclazide modified release: From once-daily administration to 24-hour blood glucose control
Harrower, A. (2000) · Metabolism · doi:10.1053/meta.2000.17823 · Cited by 30
Metadata
- Authors
- Jennings, A. M., Wilson, R. M., & Ward, J. D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1989-03-01
- Volume
- 12
- Issue
- 3
- Pages
- 203-208
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2025168202
- Cited by
- 193
- References
- 0
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.